Abstract
The application of immunotherapy for the treatment of malignant diseases has attracted growing interest in recent years. Because T-cell immunity plays a major part in the control of tumor growth, strategies have been developed to specifically target and activate T-cells towards tumor cells by circumventing major histocompatibility complex (MHC)- restricted antigen recognition. Here we review the immunoreceptor (“T-body”) strategy based on grafting cytolytic T-cells with an antigen-specific, recombinant receptor with signalling properties. The extracellular domain of the receptor molecule consists of a single-chain antibody fragment (scFv) derived from a monoclonal antibody that binds to a tumor associated antigen. The intracellular domain is derived from a signalling receptor for cellular activation, e.g., the FcεRI receptor γ-chain or the CD3 σ-chain. Thereby, the immunoreceptor strategy combines the advantages of MHCindependent binding of antibodies to antigens with efficient T-cell activation. Due to the receptor design, T-cells grafted with immunoreceptors can be directed virtually against every cell defined by the particular antigen, including tumor cells and virally infected cells. This review summarizes the current knowledge about redirecting T-cell functions by grafting in recombinant immunoreceptors with specificity for tumor associated antigens and discusses the limitations and perspectives of the strategy for use in adoptive immunotherapy of malignant diseases.
Keywords: immunoreceptor, recombinant tcr, costimulation, tumor-specific t-cells, immunotherapy
Current Pharmaceutical Design
Title: Immune Response Manipulation: Recombinant Immunoreceptors Endow T-Cells with Predefined Specificity
Volume: 9 Issue: 24
Author(s): Hinrich Abken, Andreas Hombach and Claudia Heuser
Affiliation:
Keywords: immunoreceptor, recombinant tcr, costimulation, tumor-specific t-cells, immunotherapy
Abstract: The application of immunotherapy for the treatment of malignant diseases has attracted growing interest in recent years. Because T-cell immunity plays a major part in the control of tumor growth, strategies have been developed to specifically target and activate T-cells towards tumor cells by circumventing major histocompatibility complex (MHC)- restricted antigen recognition. Here we review the immunoreceptor (“T-body”) strategy based on grafting cytolytic T-cells with an antigen-specific, recombinant receptor with signalling properties. The extracellular domain of the receptor molecule consists of a single-chain antibody fragment (scFv) derived from a monoclonal antibody that binds to a tumor associated antigen. The intracellular domain is derived from a signalling receptor for cellular activation, e.g., the FcεRI receptor γ-chain or the CD3 σ-chain. Thereby, the immunoreceptor strategy combines the advantages of MHCindependent binding of antibodies to antigens with efficient T-cell activation. Due to the receptor design, T-cells grafted with immunoreceptors can be directed virtually against every cell defined by the particular antigen, including tumor cells and virally infected cells. This review summarizes the current knowledge about redirecting T-cell functions by grafting in recombinant immunoreceptors with specificity for tumor associated antigens and discusses the limitations and perspectives of the strategy for use in adoptive immunotherapy of malignant diseases.
Export Options
About this article
Cite this article as:
Abken Hinrich, Hombach Andreas and Heuser Claudia, Immune Response Manipulation: Recombinant Immunoreceptors Endow T-Cells with Predefined Specificity, Current Pharmaceutical Design 2003; 9 (24) . https://dx.doi.org/10.2174/1381612033454289
DOI https://dx.doi.org/10.2174/1381612033454289 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Quinones Derived from Plant Secondary Metabolites as Anti-cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Mammalian Target of Rapamycin (mTOR) Inhibitors as Anti-Cancer Agents
Current Cancer Drug Targets Glucocorticoid Receptor Functions in HeLa Cells Are Perturbed by 2,3,8,9-tetrachlorodibenzo-p-dioxin (TCDD)
Drug Metabolism Letters Mitophagy in Carcinogenesis and Tumour Progression- A New Paradigm with Emerging Importance
Anti-Cancer Agents in Medicinal Chemistry Co-delivery Strategies Based on Multifunctional Nanocarriers for Cancer Therapy
Current Drug Metabolism Chemoresistance in Non-Small Cell Lung Cancer
Current Medicinal Chemistry - Anti-Cancer Agents Recent Patent-Based Perspective on Diagnostic and Therapeutic Interventions in Malignant Mesothelioma: Is Drug Repositioning Knocking on the Door?
Recent Patents on Anti-Cancer Drug Discovery Bioadhesive Films as Drug Delivery Systems
Drug Delivery Letters HIF-1α Modulates Energy Metabolism in Cancer Cells by Inducing Over-Expression of Specific Glycolytic Isoforms
Mini-Reviews in Medicinal Chemistry Harnessing the Potential of Long Non-coding RNAs to Manage Metabolic Diseases
Current Pharmaceutical Design 15,16-dihydrotanshinone I Induces Apoptosis and Inhibits the Proliferation, Migration of Human Osteosarcoma Cell Line 143B in vitro
Anti-Cancer Agents in Medicinal Chemistry An Update on Overcoming MDR1-Mediated Multidrug Resistance in Cancer Chemotherapy
Current Pharmaceutical Design Advances in Electrospinning of Nanofibers and their Biomedical Applications
Current Tissue Engineering (Discontinued) Decoding the Emerging Patterns Exhibited in Non-coding RNAs Characteristic of Lung Cancer with Regard to Their Clinical Significance
Current Genomics Gambogic Acid is a Novel Anti-cancer Agent that Inhibits Cell Proliferation, Angiogenesis and Metastasis
Anti-Cancer Agents in Medicinal Chemistry Targeting DNA Repair Proteins: A Promising Avenue for Cancer Gene Therapy
Current Gene Therapy DNMT Inhibitors in Cancer, Current Treatments and Future Promising Approach: Inhibition of Specific DNMT-Including Complexes
Epigenetic Diagnosis & Therapy (Discontinued) Role of Flavonoids in Future Anticancer Therapy by Eliminating the Cancer Stem Cells
Current Stem Cell Research & Therapy Telomerase Inhibition in Cancer Therapeutics: Molecular-Based Approaches
Current Medicinal Chemistry Gamma Secretase Inhibitor: Therapeutic Target via NOTCH Signaling in T Cell Acute Lymphoblastic Leukemia
Current Drug Targets